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ABSTRACT 
 
  
MEGHAN HOUSTON MCNEELY:  
Cardiolipin Profiling in Metastatic Breast Cancer Cells 
 
 
Six human breast cancer cell lines (MDA-MB-231, LM, BoM, T47D, MCF7, and 
MCF7-BoM) were treated with three differentially targeted phospholipase inhibitors 
(bromoenol lactone, tricyclodecan-9-yl-xanthogenate, and halopemide) as well as various 
dietary oils (canola oil, avocado oil, coconut oil, olive oil, sesame oil, and soybean oil). 
Cell viability assays were performed to examine the effects of each inhibitor and oil in 
varying concentrations on the proliferation of each breast cancer cell line. The goal was 
to detect changes in cardiolipin concentration within each cell line after exposure to a 
series of various phospholipase inhibitors and oils. Liquid chromatography-mass 
spectrometry (LC-MS) was performed on a cardiolipin standard as well as lipid extract 
samples from each cell line in order to detect changes in cardiolipin composition before 
and after the addition of test compounds. Because the MS results for the cell lines did not 
display a peak for the cardiolipin standard, we could not use these results as a valid 
means for determining the changes in cardiolipin composition between the samples. 
However, BEL, halopemide, D609, canola oil, avocado oil, coconut oil, and olive oil did 
prove to cause a statistically significant difference in the cell viability of various breast 
cancer cell lines. 
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CHAPTER I 
Introduction 
 
 
Meghan Houston McNeely 
 
 
1.1  Breast Cancer Background 
Breast cancer is the leading cause of cancer-related death in women in Western 
countries, with roughly 41,000 deaths resulting from breast cancer each year within the 
United States1. Approximately 250,000 cases of breast cancer are diagnosed annually in 
the United States, and breast cancer accounts for about one in every three cancers 
diagnosed in American women1,2. Despite improvements in early breast cancer screening, 
the prevalence of breast cancer diagnoses has nonetheless remained relatively stable since 
the 1970’s3. In fact, many predict that in the coming years, the rate of breast cancer 
diagnoses will only continue to rise, presenting an enormous need for the discovery of 
effective treatment options1. 
As they are widely available and relatively inexpensive, mammograms have become 
the preferred method for screening patients for early indications of breast cancer2. 
Mammograms are based on X-ray photographs of the patient’s breast, and they can be 
used to detect early abnormalities in the breast before they are able to be felt as lumps by 
a woman or her physician2. Along with their role in screening for signs of breast cancer, 
mammograms are also crucial in following the progression of cancer in patients whom 
have already been diagnosed4. While the rate of breast cancer diagnoses has not 
	  2 
decreased since the 1970’s, the rate of breast cancer mortalities has significantly 
decreased4. This suggests that improvements in screening methods, such as 
mammography, have allowed breast cancer cases to be diagnosed and treated more 
efficiently, leading to a concurrent decrease in these patients’ mortality. 
Radiation therapy is widely used in the treatment of many cancers such as primary 
and secondary breast cancer1. However, treatment options such as cytotoxic 
chemotherapy, are often inadequate when it comes to treating malignant tumors which 
have spread to distant areas within the body1. Many improvements have been made in 
breast cancer therapies, leading to longer survival rates for patients diagnosed with 
metastatic breast cancer3. However, approximately 90% of deaths associated with breast 
cancer still result from metastasis of the tumor cells1. Non-traditional treatments are 
being studied in the hope of discovering alternative treatments for cancer patients, 
especially for those fighting metastatic cancers.  
 
1.2  Metastasis 
Cancer is defined by eight hallmarks: “growth factor independence or self-
sufficiency, insensitivity to anti-growth signals, avoidance of programmed cell death, 
ability to recruit a dedicated blood supply, immortalization by reactivation of telomerase, 
ability to invade adjacent normal tissues and metastasize to distant sites, reprogrammed 
energy metabolism, and evading immune destruction”5. Approximately 6% of patients 
whom have been diagnosed with early-stage breast cancer experience such metastatic 
potential, in which their cancer has already spread to distant sites within the body3. The 
metastatic ability of many cancer cells often contributes largely to the mortality 
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associated with a cancer diagnosis, due partly to an overall lack of understanding when it 
comes to the cellular and molecular mechanisms of cancer metastasis6,7. The metastatic 
process is comprised of multiple elements, such as: tumor cell intravasation (or the 
entering of the tumor cell into the bloodstream), survival in bodily circulation, 
extravasation into an organ distantly located within the body, and a resulting unrestricted 
growth within an organ6,8. Breast cancer metastasis frequently occurs in the lungs, brain, 
liver, and bones6.  
Evidence indicates that breast cancer metastasis to the brain can typically occur years 
after a tumor in the breast has been removed9. This, therefore, suggests that the cancer 
cells must acquire specialized functions to successfully allow metastasis to the brain9. It 
is conventionally recognized that metastasis involves an interaction between the tumor 
cell and its host microenvironment7,10. However, the specific alterations that provide a 
cancer cell with the necessary attributes to establish metastatic lesions within its 
environment are not widely understood. One explanation of such cancer cell alterations 
lies within a modification of its mitochondrial function. Studies have shown that an 
impairment to the apoptotic mechanisms present within the mitochondria of a cell can 
ultimately facilitate the conversion of a normal cell into a cancerous cell11.  
 
1.3  Mitochondria and Cardiolipin Background 
In addition to being the cellular ‘powerhouse’ for ATP production, mitochondria are 
crucial to anabolic metabolism, as well as serving a vital role in integrating both pro-
death and pro-survival signals. The role of the mitochondria in regulating cell death 
signals allows it to definitively control apoptosis. Due to its role in programmed cell 
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death, it is said that the mitochondria “hide(s) the weapons of cellular suicide”12. When 
tumor cells suppress apoptotic signals from the mitochondria, the cell is able to avoid cell 
death and therefore promote the proliferation of a tumor within the body11. This 
contributes to one of the previously mentioned major hallmarks of cancer, specifically the 
insensitivity of cancer cells to anti-proliferative signals.  
Cardiolipins (CLs) are an essential component in mitochondrial structure and 
function. These bridged phospholipid dimers, which are located almost exclusively 
within the inner mitochondrial membrane, are the only phospholipid found primarily in a 
single location within the cell. Cardiolipin molecules are dispersed asymmetrically 
among the inner mitochondrial membrane, contributing to their ability to perform various 
signaling functions13. Aside from contributing to cellular signaling, cardiolipin molecules 
are also crucial in maintaining structural integrity within the inner mitochondrial 
membrane14. 
Cardiolipin structure has been widely preserved in eukaryotic cells. Their structure 
contains a glycerol backbone that bridges two phosphatidylglycerols in order to form a 
dimeric molecule14. The tails of the structure are comprised of four acyl chains, and the 
polar head carries two negative charges due to the associated phosphate groups13,15. In 
comparison to prokaryotic cardiolipin, eukaryotic cardiolipins possess longer acyl chains 
that are less saturated. The polyunsaturated nature of the eukaryotic cardiolipin tails 
allows the molecule to undergo oxidation by cytochrome c oxidase13. This 
polyunsaturation and oxidation is crucial in regulating the release of pro-apoptotic signals 
from the cardiolipin in the mitochondrial membrane into the cytosol11. Disturbances 
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within the cardiolipin structure and function, therefore, can result in various defects in the 
signaling functions of the mitochondria, such as those that regulate cell death13. 
 
 
 
 
 
 
 
 
 
Figure 1. Chemical Structure of Cardiolipin16. The four fatty acyl chains of the CL 
represented by R1, R1¢, R2 and R2¢, can exist in varying lengths and degrees of 
unsaturation. This provides an opportunity for the creation of many diverse CL 
molecules. The polyunsaturated nature of the tails results in high susceptibility of the 
molecule to cytochrome c oxidase-mediated oxidation16. 
 
1.4  Cardiolipin Remodeling  
Unlike most membrane lipids, which are synthesized in the endoplasmic reticulum, 
cardiolipin is synthesized primarily in the inner mitochondrial membrane and is involved 
in various, diverse functions of the mitochondria17. This diversity of functions is due 
primarily to the unique structure of this phospholipid. The four fatty acid tails of the 
cardiolipin along with the negative charges associated with the two phosphate heads 
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allow numerous interactions between the phospholipid and various cellular proteins17. 
Regulation of the synthesis and remodeling of a cell’s cardiolipin, as well as acyl 
degradation and oxidation, largely contributes to the unique cardiolipin profile within a 
particular cell17. 
 The process of synthesizing cardiolipin de novo is highly conserved between 
yeast and mammals. The first reaction involved in synthesizing CL requires the 
conversion of mitochondrial phosphatidic acid (PA) to CDP-diacylglycerol (CDP-DAG). 
This is executed via Tam41, the mitochondrial CDP-DAG synthase. Pgs1 (previously 
known as the PEL1 gene) then catalyzes the transfer of a phosphatidyl group from CDP-
DAG to glycerol-3-phosphate. This forms phosphatidylglycerol phosphate, or PGP, that 
is, in turn, dephosphorylated to form PG, or phosphatidylglycerol. In yeast, this step is 
catalyzed by Gep4 (as seen in Figure 2A). In mammals, PTPMT1 (protein tyrosine 
phosphatase, mitochondrial 1) serves as the catalyst of this dephosphorylation. Finally, 
Crd1 (cardiolipin synthase) catalyzes the final reaction in the de novo synthesis pathway 
by adding a phosphatidyl group from CDP-DAG to PG to form the CL. The acyl chains 
of the newly synthesized CL are primarily saturated (CLSAT). However, CLSAT is 
deacylated by Cld1 (cardiolipin-specific deacylase 1) to form a monolysocardiolipin 
(MLCL). This MLCL can be reacylated by tafazzin, a Taz1 gene product located in the 
outer face of the inner mitochondrial membrane as well as the inner face of the outer 
mitochondrial membrane17. 
The enzymes involved in cardiolipin synthesis do not exhibit acyl specificity, 
allowing CL remodeling to occur in which acyl chains are removed from the 
phospholipid and replaced17. This remodeling occurs either through a two-step process or 
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a one-step process. The two-step process, or the deacylation-reacylation Lands cycle, 
involves a phospholipid being deacylated (at which point it is referred to as a 
lysophospholipid). Then, acyl groups from nearby phospholipids are added to the 
lysophospholipid in a reacylation step. In the one-step process, acyl chains are exchanged 
between neighboring phospholipids in a process known as transacylation17. Tafazzin 
(Taz1) can serve as a transacylase and transfer an acyl group between phospholipid and 
lysophospholipid, contributing to the one-step CL remodeling mechanism. Likewise, 
tafazzin can also contribute to the two-step method of remodeling. Tafazzin’s crucial role 
in the two-step method of CL remodeling is further proven through the fact that a tafazzin 
deficiency ends the acylation step of the two-step method17.  
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Figure 2. Cardiolipin Biosynthesis and Remodeling17. The synthesis of cardiolipin in 
the inner mitochondrial membrane is highly conserved between yeast to mammals. 
Cardiolipin synthesis is shown in (A) as it occurs in the yeast Saccharomyces cerevisiae. 
The synthesis of CLSAT represents the end cardiolipin product, which typically possesses 
saturated acyl chains. The conversion of CLSAT to CLUNSAT by tafazzin (Taz1) 
summarizes the process of CL remodeling. Cardiolipin remodeling, shown in more detail 
in (B) can occur via two mechanisms: a two-step deacylation-reacylation cycle or a one-
step transacylation. Taffazin can transacylate CL in one step, or it can reacylate MLCL in 
the two-step process. (Permission to use figures received from publisher).  
(A)
(B)
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It has been demonstrated that specific alterations to lipids contribute to multiple 
cellular functions and disease states. Even slight alterations to fatty acid chains, such as 
those within the cardiolipin structure, can lead to very contrasting properties between 
molecular phospholipid species16. Various analytical methods such as chromatography 
and mass spectrometry have been used in order to gain insight into such alterations and 
their resulting effects, contributing largely to the field of lipidomics. These analyses are 
useful in acquiring information on lipid distribution and content within cells16. Mass 
spectrometry serves as the primary method for analyzing lipids, and it functions by “the 
detection of ions (as charged lipid molecules) after their separation within an 
electromagnetic field”16. Specifically, the field of lipidomics has been used in studies by 
Kagan and coworkers in order to analyze cardiolipin content within the brain following 
traumatic brain injuries16. These studies demonstrate that peroxidation of cardiolipin is 
necessary for the release of pro-apoptotic signals from the mitochondria16.   
 Kagan and coworkers stimulated proapoptotic signals in the mitochondria of 
tumor cells as a potential target in anticancer treatment11. Specifically, this therapy aims 
to target an early stage of mitochondria-dependent apoptosis, which involves the 
oxidation of cardiolipin by cytochrome c oxidase11. Such efforts aim to suppress 
proapoptotic signals in the normal cells which surround the cancerous cells11. Further 
evidence of the role of cardiolipin abnormalities in cancer is provided by animal-based 
studies, such as the discovery by Peyta and coworkers of an increase in cardiolipin 
content in cancer rat models and in a murine brain tumors13. 
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1.5  Conclusions 
The overall impact and deadly prevalence of breast cancer in women warrants a need 
for an exploration of new therapeutic options. Modern treatments are relatively 
ineffective in treating highly metastatic forms of breast cancer. Further, the metastasis of 
breast tumors contributes largely to the disease mortality. Efforts have been made to 
determine which alterations within a cancer cell allow for its metastatic potential, and the 
answer may lie within the mitochondrial membrane of the tumor cell. Cardiolipins, 
unique to this membrane, regulate pro/anti-apoptotic signals which can contribute largely 
to the proliferation (or lack thereof) of cells such as breast cancer cells. The field of 
lipidomics uses analytical methods such as mass spectrometry to examine phospholipid 
content (such as cardiolipin content) within cells. Alterations in cardiolipin composition 
may play a crucial role in regulating breast cancer cell survival and metastasis.  
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CHAPTER II 
 
Cardiolipin Profiling in Metastatic Breast Cancer Cells 
Jawaher Alkhamisy, Meghan McNeely, Dale G. Nagle, and Yu-Dong Zhou 
 
*MM performed cell viability experiments, mitochondrial isolation, cardiolipin 
extraction, and statistical analyses  
 
2.1  Introduction 
In an attempt to study the effect of cardiolipin profile on the metastatic potential of 
breast cancer cells, the effects of three differentially targeted phospholipase inhibitors 
were evaluated in various breast cancer cell lines. Cell viability assays ware performed in 
order to examine the effects of each inhibitor on the proliferation/viability of each cell 
line. Bromoenol lactone (BEL), the first inhibitor used, serves as an inhibitor of calcium-
independent phospholipase A2 (iPLA2)18. The iPLA2 family of phospholipases functions 
in membrane phospholipid remodeling19. The second inhibitor used was tricyclodecan-9-
yl-xanthogenate (D609), which is a competitive inhibitor of phosphatidylcholine-specific 
phospholipase C (PC-PLC)20. Phospholipase C functions in converting 
phosphatidylinositol 4,5-bisphosphate (PIP2) to inositol 1,4,5-trisphosphate (IP3) 
diacylglycerol (DAG)21. The DAG and IP3 are both crucial second messengers which are 
important in the regulation of various cellular metabolic pathways21. Lastly, halopemide 
was used as an inhibitor of phospholipase D (PLD)22. Phospholipase D plays a vital role 
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in the production of phosphatidic acid (PA) and choline by the hydrolysis of 
phosphatidylcholine (PC), and it also functions in altering cell growth and 
morphology22,23. This production of PA and choline is important in beginning many lipid 
signaling pathways mediated by PA as well as other cellular messengers such as DAG22. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Chemical Structures of Selected Phospholipase Inhibitors. The three 
selected inhibitors target specific phospholipases involved in cardiolipin biosynthesis and 
remodeling. The molecular structures of (A) Bromoenol lactone (BEL), an inhibitor of 
calcium-independent phospholipase A2 (iPLA2)18, (B) Tricyclodecan-9-yl-xanthogenate 
(D609), an inhibitor of phosphatidylcholine-specific phospholipase C (PC-PLC)20, and 
(C) Halopemide, an inhibitor of phospholipase D (PLD)22 are shown above.  
 
(A) 
(C)
(B) 
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Figure 3.2 Hydrolyzation of Phosphatidylinositol 4,5-bisphosphate (PIP2) by 
Phospholipase C21. Phospholipase C (PLC) hydrolyzes phosphatidylinositol 4,5-
bisphosphate (PIP2) to yield the second messengers inositol 1,4,5-trisphosphate (IP3) and 
diacylglycerol (DAG). This pathway is shown in red. IP3 and DAG are second 
messengers, which are substrates for other molecules such as phosphatidic acid (PA) and 
inositol polyphosphates. Related regulatory targets are shown in green, while other 
singling molecules are represented in blue21.  
 
In addition to the phospholipase inhibitors, the cell lines were also treated with 
various dietary oils in order to determine the effect of these oil types and concentrations 
on breast tumor cell proliferation. Evidence has established a link between dietary lipid 
consumption and the species of cardiolipin that is produced during CL synthesis24. 
Additionally, the consumption of dietary oils, specifically canola oil, has been linked to 
decreased tumor incidence in patients with colon cancer25. These studies indicate that a 
canola oil-rich diet significantly decreased both colon cancer incidence and multiplicity 
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in rats when compared to the effects of corn oil25. Canola oil contains a higher ratio of ω-
3 fatty acids to ω-6 fatty acids (a 1:2 ratio) as compared to corn oil25. The ideal ratio of ω-
3 fatty acids to ω-6 fatty acids is about 1:1 to 1:4, whereas the average American diet 
consist of the oils in a ratio between 1:10 and 1:2525. Studies have shown that the 
chemopreventative mechanism of ω-3 fatty acids in canola oil has to do with the 
inhibition of cyclooxygenase (COX) as well as the synthesis of arachidonic acid (AA)25. 
Additionally, ω-3 fatty acids are proven to reduce prostaglandin production and 
inflammation26. High levels of ω-6 fatty acids, on the other hand, are linked to increased 
prostaglandin production, which increases the cytokine activity associated with 
inflammation26. Research has shown that diets high in ω-6 fatty acids may also increase 
the growth rate of cancers other than colon cancers, including breast cancer25.  
Six dietary oils were selected (canola oil, avocado oil, coconut oil, olive oil, 
sesame oil, and soybean oil). Whereas canola oil has a relatively low ratio of ω-3 fatty 
acids to ω-6 fatty acids (1:2), olive oil has a much higher ω-6 fatty acid content, with a 
ratio of 1:10. Soybean oil also has a very high ω-6 fatty acid content27. However, coconut 
oil, like canola oil, is also relatively low in ω-6 fatty acid content27.  
The saturated vs. unsaturated nature of these six dietary oils is also relevant to the 
degree of breast cancer cell proliferation. In a study by Serge Hardy and coworkers, the 
effect of saturated and unsaturated free fatty acids (FFAs) on the proliferation and 
apoptosis of the breast cancer cell line MDA-MB-231 was examined28. The study found 
that unsaturated fatty acids increase breast cancer cell proliferation. Saturated fatty acids, 
on the other hand, inhibit proliferation and cause apoptosis28. The saturated fatty acids 
decrease the levels of mitochondrial CL, which is necessary for cytochrome c retention. 
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The release of cytochrome c, a mitochondrial proapoptotic protein, results in the 
activation of caspases which cause cell death28. The six oils used in this study possess 
varying degrees of unsaturation. Soybean oil is the least saturated of the six and is about 
60% polyunsaturated29. Coconut oil, on the other hand, is about 75% saturated29. Olive 
oil, avocado oil, and canola oil, are all monounsaturated (77%, 68%, and 60% 
monounsaturated relatively)29.  
After performing cell viability experiments for each breast cancer cell line with 
the various phospholipase inhibitors and oils, mitochondria were isolated from the 
various cell cultures and liquid chromatography-mass spectrometry was performed in 
order to analyze their cardiolipin profiles. The goal was to study the working hypothesis 
for this experiment: that cardiolipin composition plays a major role in the mitochondrial 
functioning of metastatic breast cancer cells.  
The cell lines selected were MDA-MB-231, LM, BoM, T47D, MCF7, and MCF7-
BoM. MDA-MB-231 is a widely studied triple-negative breast cancer (TNBC) cell line30. 
The BoM and LM cell lines are bone metastatic and lung metastatic subclones derived 
from the MDA-MB-231 cell line6,7. The T47D is an estrogen-dependent cell line which 
exhibits many low-level genetic abnormalities30. The MCF7, on the other hand, possesses 
many genetic abnormalities with high amplification30. The MCF7-BoM is a metastatic 
variant of the MCF7 breast cancer cell line31.  
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CELL LINE 
GENE 
CLUSTER ER PR SOURCE 
TUMOR 
TYPE AGE 
MDA-MB-231 BaB - [-] PE AC 51 
T47D Lu + [+] PE IDC 54 
MCF7 Lu + [+] PE IDC 69 
 
Table 1. Source and Pathological Features of Tumors Used to Derive Selected Breast 
Cancer Cell Lines30. MDA-MB-23, T47D, and MCF7 were all derived from the pleural 
effusion of a metastatic breast cancer patient. The T47D and MCF7 cell lines were 
derived from a luminal gene cluster, whereas MDA-MB-231 was derived from a basal 
gene cluster. (BaB= basal. Lu= luminal. PE= pleural effusion. AC=adenocarcinoma. 
IDC= invasive ductal carcinoma)30.  
 
2.2  Results  
Data comparison was performed on cell viability data with one-way ANOVA 
followed by Bonferroni post hoc analyses using GraphPad Prism 7. Differences between 
data sets were considered statistically significant when p < 0.05.   
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Figure 4. Impact of Bromoenol Lactone (BEL) on Breast Tumor Cell Viability. (A) 
Structure of BEL. (B) Percent control of BEL inhibitor (B1552) on breast cancer cell 
lines. Data are shown as average ± standard deviation (n=4). (*represents statistical 
significance). 
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Figure 5. Impact of The Tricyclodecan-9-yl-xanthogenate (D609) on Breast Tumor 
Cell Viability. (A) Structure of D609. (B) Percent control of D609 inhibitor (T8543) on 
breast cancer cell lines. Data are shown as average ± standard deviation (n=4). 
(*represents statistical significance). 
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Figure 6. Impact of Halopemide on Breast Tumor Cell Viability. (A) Structure of 
halopemide. (B) Percent control of halopemide inhibitor (H3041) on breast cancer cell 
lines. Data are shown as average ± standard deviation (n=4). (*represents statistical 
significance). 
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Figure 7. Impact of Canola Oil on Breast Tumor Cell Viability. Percent control of 
canola oil on breast cancer cell lines. Data are shown as average ± standard deviation 
(n=2). (*represents statistical significance). 
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Figure 8. Impact of Avocado Oil on Breast Tumor Cell Viability. Percent control of 
avocado oil on breast cancer cell lines. Data are shown as average ± standard deviation 
(n=2). (*represents statistical significance). 
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Figure 9. Impact of Coconut Oil on Breast Tumor Cell Viability. Percent control of 
coconut oil on breast cancer cell lines. Data are shown as average ± standard deviation 
(n=2). (*represents statistical significance). 
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Figure 10. Impact of Olive Oil on Breast Tumor Cell Viability. Percent control of olive 
oil on breast cancer cell lines. Data are shown as average ± standard deviation (n=2). 
(*represents statistical significance). 
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Figure 11. Impact of Soybean Oil on Breast Tumor Cell Viability. Percent control of 
soybean oil on breast cancer cell lines. Data are shown as average ± standard deviation 
(n=2).  
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Figure 12. Impact of Sesame Oil on Breast Tumor Cell Viability. Percent control of 
sesame oil on breast cancer cell lines. Data are shown as average ± standard deviation 
(n=2). 
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Figure 13. Mass Spectrometry Analysis of Cardiolipin Standard and Cell Extracts. 
Liquid chromatography-mass spectrometry was performed on the breast cancer cells prior 
to the addition of the three inhibitors. The cardiolipin standard peak can be seen at 3.32 
minutes on the MS of the cardiolipin-only sample. The cardiolipin peak did not appear on 
the MS results for the cell lines, which does not allow for comparison of the cell 
cardiolipin compositions before and after the addition of the phospholipase inhibitors.   
 
2.3  Discussion 
The goal of these experiments was to detect changes in cardiolipin composition 
within breast cancer cell lines by their exposure to three differentially targeted 
phospholipase inhibitors. The first step of our experiment was to set up a method for 
detecting changes in cardiolipin composition within the cell lines. Liquid 
chromatography-mass spectrometry (LC-MS) was performed on each cell line as well as 
a cardiolipin standard. The next step was to treat the cells with the inhibitors and assess 
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for changes in cardiolipin composition by comparing the mass spectrometry results 
before and after the addition of the compounds. The cardiolipin standard peak can be 
definitively observed in the MS results for the cardiolipin-only sample. However, the MS 
results for the breast cancer cell lines did not display the peak for the cardiolipin standard. 
Therefore, we cannot use the MS data we gathered as a valid means for comparing 
cardiolipin composition before and after the addition of the inhibitory compounds. 
However, statistically significant differences in cell viability results were observed in the 
breast tumor cell lines as a result of treatment with each of the three phospholipase 
inhibitors (BEL, halopemide, D609), as well as canola oil, avocado oil, coconut oil, and 
olive oil. (See figures 4-10). Soybean oil and sesame oil did not provide statistically 
significant results. 
 
2.4  Materials and Methods  
2.4.1 Cell viability assay 
Cell culture was performed for each cell line before the cell viability assay was 
executed. Cells were maintained in medium with RPMI-1640 with glutamine (Corning), 
with 10% (v/v) fetal calf serum (FCS, Hyclone), and 50 units mL-1 penicillin and 50 µg 
mL-1 streptomycin (Sigma). Before adding the cells to each culture, 9 mL of the prepared 
media was placed in the incubator for 10 to 15 minutes. The cells were then taken from 
the liquid nitrogen and defrosted in the incubator for about five minutes. Cells (1 mL) of 
each respective cell line was added to the media in the 100 mm plate. Each plate was 
incubated at 37°C overnight (95% Air/5% CO2). The next morning, the cells were 
checked under the microscope to ensure they were healthy. The media was aspirated from 
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each culture, and regular media (without FCS or antibiotic) was used to wash the cells. 
Once the cells were washed, 10 mL of the prepared media was again added to each 
culture.  
Next, the media was again aspirated and 1 mL of Trypsin-EDTA (0.25%, Gibco) was 
used in order to detach the cells. The cultures were put in the incubator for five minutes. 
Once the cells were floating, 10 mL of the prepared media was added to inactive the 
trypsin. The cells and media were gathered using a pipette and transferred to a 15 mL 
centrifuge tube. The tubes were centrifuged at 600 rpm for 5 minutes (Jouan C412) and 
the media was aspirated. To detach the cells, 5 µL of the prepared media was added.  
When performing the cell viability assay, the basic rule followed was to gather 3x106 
cells per 10 mL solution. A 12 mL solution was therefore prepared with 3.6x106 cells. 
Using the cell density from the cultures performed (0.68x106 cells/mL), the volume of 
cells to be gathered was found to be 5.15 mL by dividing the cell number (3.6x106) by 
the cell density. The solution was completed to 12 mL using 6.85 mL of prepared media. 
The solution containing 5.15 mL cells and 6.85 mL media was placed in a reservoir. 
Using a pipette, 100 µL of the solution was added to each well on a 96-well plate. The 
plate was shaken on a vortex on low speed for 1 minute. The stock solutions for the 
inhibitors were then prepared. 
Because BEL is stable at a maximum concentration of 25 g/L, the stock solution was 
prepared to be 20 g/L. This concentration along with the inhibitor’s molecular weight 
(317.18 g/mole) was used to calculate the molarity as 63 x 104 µM. To simplify the 
calculations, we used 60 x 104 mM. This yielded 5 mg dissolved in 262.7 µL of DMSO 
for the stock solution. A 1:10 dilution was performed in order to provide samples with the 
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desired concentrations (30, 10, 3, and 1 µM) from the stock solution. First, 1.5 µL of the 
compound was added to 1,498.5 µL media to yield the 30 µM sample. 400 µL of this mix 
was added to a new tube along with 800 µL media in order to yield the 10 µM sample. 
Another 100 µL from the 30 µM sample was added to a third tube along with 900 µL 
media in order to yield a 3 µM sample. Lastly, 100 µL from the 10 µM sample was 
transferred to a fourth tube with 900 µL media. This yielded the last concentration needed 
for BEL: 1 µM. 
The stock solution for halopemide was prepared next. Halopemide is stable at a 
maximum concentration of 10 g/L. This concentration along with the MW of halopemide 
(416.88 g/mole) was used to calculate the molarity as 20 M. This yielded 5 mg 
halopemide dissolved in 599.7 µL of DMSO for the stock solution. A 1:10 dilution was 
again performed, this time to create samples with concentrations of 10, 3, 1, 0.3, 0.1, and 
0.03 µM. 
The D609 solution was then prepared. D609 is stable at a maximum concentration of 
20 g/L. This concentration along with the MW of D609 (266.48 g/mole) was used to 
calculate the molarity as 75 mM. The stock solution was prepared using by adding the 5 
mg of D609 to 250 µL of DMSO. 3.99 µL of the stock solution was added to 1498.5 µL 
media to form a 100 µM solution. Next, 300 µL of this mix was added to 700 µL of 
media in a separate tube to produce a 30 µM solution. A 1:10 dilution was used to make a 
10 µM solution and a 1µM solution from the original 100 µM solution. A 1:10 dilution 
was, again, used to make a 3 µM solution from the 30 µM solution.  
The inhibitors in various concentrations were added to the cells which have been 
seeded onto 96-well plates. Various oils in differing concentrations were also added to 
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the cells in order to examine the effect of the oils on tumor cell proliferation. Canola oil, 
avocado oil, coconut oil, olive oil, sesame oil, and soybean oil were used at 
concentrations of 3%, 1%, and 0.3%. Additionally, a media control was included in the 
96-well plate as well as 10 µM cycloheximide (CHX). In order to fix the cells, 100 µL of 
media was removed from each well and 100 µL of 20% TCA was added to the wells. The 
cells were incubated at 4°C for one hour. The plates were then washed by placing the 
plates into a bucket of tap water four times. Each plate was left to air dry at room 
temperature. Next, in order to stain the cells, 80 µL of SRB was added to the cells at 
room temperature for 10 minutes. After rinsing with 1% acetic acid three times, 100 µL 
of Tris base solution was added to the cells. The plates were placed on a shaker and the 
absorbance of each plate was taken using the microarray at 510 nm.  
 
2.4.2 Mitochondrial isolation32 
The PIERCE Mitochondria Isolation Kit for Cultured Cells was used in order to 
extract intact mitochondria from the cell cultures. Approximately 20 x106 cells were 
gathered from each of the five cell lines in order to create the five samples. First, the 
protease inhibitor was added to Reagants A and C. The protease inhibitor (240 mL) was 
added to 4.8 mL of Reagant A, and 390 µL of the protease inhibitor was added to 7.8 mL 
of Reagant C. Cells from each cell line were suspended in 2,000 µL of 1x concentrated 
Dulbecco's Phosphate-Buffered Saline (DPBS) and transferred to separate 2 mL 
centrifuge tubes. The samples were centrifuged for two minutes and the supernatant was 
removed. Next, 800 µL of Reagant A was added to each sample, and the samples were 
put in a medium speed vortex for five seconds. Each sample was then incubated on ice 
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for two minutes. Next, 10 µL of Reagant B was added and the samples were again 
vortexed for five seconds, this time on maximum speed. The tubes were incubated on ice 
for an additional five minutes, and vortexed at maximum speed for five seconds at each 
one-minute interval. Each sample was centrifuged at 600 x g at 4°C for 10 minutes. Next, 
the supernatant from each tube was transferred to a new 2.0 mL tube and centrifuged at 
12,000 x g at 4°C for 15 minutes. The supernatant was again transferred to a new tube, 
with the pellet containing the isolated mitochondria. Reagant C (500 µL) was added to 
the pellet and the samples were centrifuged at 12,000 x g for 5 minutes. The supernatant 
was discarded. The isolated mitochondria in the pellet was kept at -80°C before 
processing. 
 
2.4.3 Cardiolipin extraction 
A cardiolipin extraction was performed from both the whole cell as well as the 
isolated mitochondria. First, 0.05 µL (or 50 µg) of tetramyristyl-CL (1,1',2,2'-
tetratetradecanoyl cardiolipin, Avanti) was added to the sample. Next, 4.2 µL 
chloroform/methanol solution (2:1 v/v) was added. Then, 7.5 µL 0.05% butylated 
hydroxytoluene (BHT) was added and the sample was vortexed for two minutes. The 
liquid and aqueous phases were separated by adding 800 µL of 0.01 M HCl. The sample 
was vortexed at high speed for two minutes and then centrifuged at 1,000 rpm and 25°C 
for 5 minutes. The lipid phase (at bottom) was collected and dried under Argon.  
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2.4.4 Mass spectrometry  
Liquid chromatography-mass spectrometry (LC-MS) was performed on the 
cardiolipin sample as well as the breast cancer cell lines in order to detect a cardiolipin 
standard within the cells. The instrument used to perform the mass spectrometry analysis 
was Waters Xevo G2-S QTOF. Cardiolipin (1 µg/mL) in isopropyl alcohol (i-PrOH) served 
as the standard for the mass spectrometry analysis. The cardiolipin standard was then 
meant to be used as a means to compare cardiolipin alterations in each sample after the 
addition of the phospholipase inhibitors.   
 
2.4.5 Data 
The percent control that each inhibitor had on the proliferation of each cell line was 
found using measures of absorbance found with a microarray. Each 96-well plate was 
stained with Sulforhodamine B (SRB) and the absorbance of each well was measured at 
510 nm. This data was then inserted into an excel sheet. The average absorbance for each 
condition as well as the control was found. These values were then used to calculate the 
percent control for each condition. This was done by dividing the average absorbance of 
the particular condition by the average absorbance for the control samples in each plate.  
 
2.4.6 Statistic analysis 
Data comparison was performed with one-way ANOVA followed by Bonferroni post 
hoc analyses using GraphPad Prism 7. Differences between data sets were considered 
statistically significant when p < 0.05. 
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